The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Scientific Advisory Board Member
Andrew Davies, BSc, BM, FRCP, PhD, is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton, Southampton, UK. He completed his training in Medical Oncology at St Bartholomew’s Hospital, London, UK, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.
Professor Davies specialises in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody-containing therapies applied to lymphoma and also in the translation of biomarkers and novel therapies to the clinical arena. He has extensive experience in early phase trials, including leading several first-in-man lymphoma studies.
He is the past Chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Director of Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex Regional Lead for Cancers in Teenagers and Young Adults.
Positions of responsibility:
Filter by content: